The developer of novel immunotherapies for the treatment of cancer and infectious disease said taking the new premises, in addition to its laboratories at the University of Nottingham, will allow it to further accelerate the development of its portfolio of immunotherapies, to support clinical trial activities and provide analytical and formulation facilities for future product development.
Scancell, which raised GBP46mln last year to drive its pipeline through clinical trials, now has 1,900 sq ft of laboratory space and 1,800 sq ft of office facilities in Oxford Science Park.
Roughly half of the company’s 40 staff are located in the new premises and it said there are plans to recruit additional people to its clinical and product development teams in the next 12 months.
Chief executive Professor Lindy Durrant said: “TOSP is the perfect location for Scancell’s expansion, with access to an excellent local talent pool as we grow the business. We are excited to be part of the creative and collaborative group of companies located in the Park and look forward to further developing our innovative products at this new site.”